Pharmaceutical Contract Development and Manufacturing Market Scope
The pharmaceutical industry is having a major share in contract manufacturing. The reason is that buying equipment for the mass production of certain chemicals is very costly, and some companies can't do it. Pharmaceutical contract development and manufacturing organizations offer one-stop solutions from development to manufacturing to all the pharmaceutical and medical device companies on a contract basis. Most of the small-sized pharmaceutical and biopharmaceutical companies prefer outsourcing their development and manufacturing organization activities due to a lack of internal capabilities. In addition, favourable regulatory affairs in developing economies and assurance of quality services are other major drivers for contract development and the manufacturing organization market. Most of the pharmaceutical and biopharmaceutical companies are outsourcing their manufacturing activities to CDMOs in order to meet the rising demand for small molecules and biologics in emerging countries. This is expected to drive market growth over the estimated period.
The Pharmaceutical Contract Development and Manufacturing market study is segmented, by Application (Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies and Other End Users) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Germany Players will contribute to the maximum growth of Global Pharmaceutical Contract Development and Manufacturing market throughout the predicted period.
Thermo Fisher Scientific Inc. (United States), Catalent, Inc. (United States), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (United States), Aenova Group (Germany), Consort Medical plc (United Kingdom) and Almac Group (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany) and Evonik Industries AG (Germany).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Pharmaceutical Contract Development and Manufacturing market by Type, Application and Region.
On the basis of geography, the market of Pharmaceutical Contract Development and Manufacturing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In October 2019 ANI launches the CDMO arm after WellSpring integration, the launch of the brand demonstrates the progress that the company has made since the WellSpring acquisition. The newly-established business was presented at the CPhI Worldwide event in Frankfurt, Germany.
- The increasing outsourcing in the pharmaceuticals industry
- The strong merger and acquisition activities in the CDMO
- Increasing Cdmo Manufacturing Footprint in Asian Countries
- Increasing Investments in Pharmaceutical R&D
- Growing Demand for Generics
- The increasing number of small and medium-sized pharmaceutical companies
- Asia-Pacific is expected to witness the highest growth in the CRO market, owing to the low cost offered by the region, as compared to the United States and other developed economies
- The growing outsourcing trend by small and large pharmaceutical companies represents a promising opportunity for Contract Development and Manufacturing Organizations As pharma shifts its focus to more research and development and less in-house manufacturing,
- Lack of Control over that product
- Capacity Constraints and Loss of Flexibility and Responsiveness
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Pharmaceutical Contract Development and Manufacturing Providers, Government Regulatory and Research Organizations and End-Use Industry
Frequently asked questions:1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Pharmaceutical Contract Development and Manufacturing Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.